ABSTRACT There are no effective disease modifying therapies for Multiple Sclerosis (MS). MS is characterized by immune system-mediated demyelination of the adult nervous system (NS). The present invention deals with an antibody directed against HERV-W. The claimed antibody targets a newly discovered detrimental mechanism which blocks the endogenous myelin repair capacity of the adult NS. This remyelination blockage is responsible for a progressive form of MS associated with the expression of HERV-W envelope protein (ENV). Therefore, targeting the HERV-W ENV with the claimed antibody would be beneficial for progressive MS patients. CA 2882781 2020-03-31
COMPOUNDS FOR TREATING THE REMYELINATION BLOCKADE IN DISEASES ASSOCIATED WITH THE EXPRESSION OF HERV-W ENVELOPE PROTEIN